DT

Digambar Tukaram Medhe

Active Director Director DIN 11181410
DIN 11181410 First appointment Jul 2025
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Digambar Tukaram Medhe

Data last updated:

Digambar Tukaram Medhe is a Director at Coreone Pharma Private Limited (since 2025).

DIN 11181410
Primary Designation Director
First Appointment 02 Jul 2025
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Coreone Pharma Private Limited U21000MH2025PTC451705
Director02 Jul 20252025Active

Board colleagues of Digambar Tukaram Medhe

Directorship timeline

Open interactive timeline →
Coreone Pharma Private Limited
Premium access

Shareholding and investment profile for Digambar Tukaram Medhe

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Digambar Tukaram Medhe

Digambar Tukaram Medhe currently holds 1 directorship: Coreone Pharma Private Limited (Director, since 02 Jul 2025).

Digambar Tukaram Medhe was first appointed on 02 Jul 2025 as Director at Coreone Pharma Private Limited.

The current boards of Digambar Tukaram Medhe's companies include Neeta Rajesh Tawade (Coreone Pharma Private Limited), Surekha Sandip Patil (Coreone Pharma Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available